tetano
Editor, Senior Moderator
Cureus
. 2023 Jan 27;15(1):e34272.
doi: 10.7759/cureus.34272. eCollection 2023 Jan.
Immune Thrombocytopenia and Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Case Report
Saurabh Kataria[SUP] 1 2 3 [/SUP], Rezaur Rahman Reza[SUP] 4 [/SUP], Adesola A Agboola[SUP] 5 [/SUP], Khalid H Mohamed[SUP] 6 [/SUP], Alaa S Mohamed[SUP] 7 [/SUP], Nimra Zahid[SUP] 8 [/SUP], Muhammad Haseeb[SUP] 8 9 [/SUP], Hira Nasir[SUP] 10 [/SUP]
Affiliations
Abstract
Mass vaccination against coronavirus disease 2019 (COVID-19) has been safe and effective. The ongoing emergence of vaccine-induced complications has challenged the public trust in vaccination programs and, though uncommon, can lead to significant morbidity and mortality. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare and fatal complication of the COVID-19 vaccine. We present a rare case of VITT in a young female who presented with worsening headache, body rash with deteriorating neurological deficit after 12 days of the second dose of the ChAdOx1 COVID-19 vaccine. Initial blood tests showed thrombocytopenia with deranged clotting time and D-dimer levels. Her computed tomography venogram showed thrombosis in the left transverse sinus, and she was diagnosed with a provisional diagnosis of VITT. She initially managed with dexamethasone, intravenous immunoglobulins, and apixaban to reverse the autoimmune process. Our case highlights the clinical course, diagnosis, and management of VITT, which will assist physicians in the timely recognition and adequate management of VITT.
Keywords: cerebral venous sinus thrombosis (cvst); covid associated thrombocytopenia; covid-2019; vaccine-induced prothrombotic immune thrombocytopenia; vaccine-induced thrombocytopenia.
. 2023 Jan 27;15(1):e34272.
doi: 10.7759/cureus.34272. eCollection 2023 Jan.
Immune Thrombocytopenia and Cerebral Venous Sinus Thrombosis Following COVID-19 Vaccination: A Case Report
Saurabh Kataria[SUP] 1 2 3 [/SUP], Rezaur Rahman Reza[SUP] 4 [/SUP], Adesola A Agboola[SUP] 5 [/SUP], Khalid H Mohamed[SUP] 6 [/SUP], Alaa S Mohamed[SUP] 7 [/SUP], Nimra Zahid[SUP] 8 [/SUP], Muhammad Haseeb[SUP] 8 9 [/SUP], Hira Nasir[SUP] 10 [/SUP]
Affiliations
- PMID: 36855477
- PMCID: PMC9968471
- DOI: 10.7759/cureus.34272
Abstract
Mass vaccination against coronavirus disease 2019 (COVID-19) has been safe and effective. The ongoing emergence of vaccine-induced complications has challenged the public trust in vaccination programs and, though uncommon, can lead to significant morbidity and mortality. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare and fatal complication of the COVID-19 vaccine. We present a rare case of VITT in a young female who presented with worsening headache, body rash with deteriorating neurological deficit after 12 days of the second dose of the ChAdOx1 COVID-19 vaccine. Initial blood tests showed thrombocytopenia with deranged clotting time and D-dimer levels. Her computed tomography venogram showed thrombosis in the left transverse sinus, and she was diagnosed with a provisional diagnosis of VITT. She initially managed with dexamethasone, intravenous immunoglobulins, and apixaban to reverse the autoimmune process. Our case highlights the clinical course, diagnosis, and management of VITT, which will assist physicians in the timely recognition and adequate management of VITT.
Keywords: cerebral venous sinus thrombosis (cvst); covid associated thrombocytopenia; covid-2019; vaccine-induced prothrombotic immune thrombocytopenia; vaccine-induced thrombocytopenia.